190 related articles for article (PubMed ID: 34865644)
1. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
Foss-Freitas MC; Akinci B; Neidert A; Bartlett VJ; Hurh E; Karwatowska-Prokopczuk E; Oral EA
Lipids Health Dis; 2021 Dec; 20(1):174. PubMed ID: 34865644
[TBL] [Abstract][Full Text] [Related]
2. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Gaudet D; Karwatowska-Prokopczuk E; Baum SJ; Hurh E; Kingsbury J; Bartlett VJ; Figueroa AL; Piscitelli P; Singleton W; Witztum JL; Geary RS; Tsimikas S; O'Dea LSL;
Eur Heart J; 2020 Oct; 41(40):3936-3945. PubMed ID: 32860031
[TBL] [Abstract][Full Text] [Related]
3. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
Bergmark BA; Marston NA; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Park JG; Murphy SA; Verma S; Wojakowski W; Terra SG; Sabatine MS; Wiviott SD;
Circulation; 2022 May; 145(18):1377-1386. PubMed ID: 35369705
[TBL] [Abstract][Full Text] [Related]
4. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study.
Oral EA; Garg A; Tami J; Huang EA; O'Dea LSL; Schmidt H; Tiulpakov A; Mertens A; Alexander VJ; Watts L; Hurh E; Witztum JL; Geary RS; Tsimikas S
J Clin Lipidol; 2022; 16(6):833-849. PubMed ID: 36402670
[TBL] [Abstract][Full Text] [Related]
5. ANGPTL3 Deficiency and Risk of Hepatic Steatosis.
D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO
Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy.
Park JY; Javor ED; Cochran EK; DePaoli AM; Gorden P
Metabolism; 2007 Apr; 56(4):508-16. PubMed ID: 17379009
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
8. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3.
Zimerman A; Wiviott SD; Park JG; Murphy SA; Ran X; Bramson CR; Curto M; Ramos V; Jevne A; Kuder JF; Verma S; Wojakowski W; Terra SG; Sabatine MS; Bergmark BA; Marston NA
J Clin Lipidol; 2024; 18(2):e261-e268. PubMed ID: 38158248
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State.
Tikkanen E; Minicocci I; Hällfors J; Di Costanzo A; D'Erasmo L; Poggiogalle E; Donini LM; Würtz P; Jauhiainen M; Olkkonen VM; Arca M
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):665-674. PubMed ID: 30816800
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
[TBL] [Abstract][Full Text] [Related]
11. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids.
Robciuc MR; Maranghi M; Lahikainen A; Rader D; Bensadoun A; Öörni K; Metso J; Minicocci I; Ciociola E; Ceci F; Montali A; Arca M; Ehnholm C; Jauhiainen M
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1706-13. PubMed ID: 23661675
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.
Sekizkardes H; Cochran E; Malandrino N; Garg A; Brown RJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3068-3076. PubMed ID: 31194872
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Serum Angiopoietin-like Proteins 3 and 8 and Atherogenic Lipid Biomarkers in Non-Diabetic Adults Depends on Gender and Obesity.
Murawska K; Krintus M; Kuligowska-Prusinska M; Szternel L; Stefanska A; Sypniewska G
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959891
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of morbidity and mortality patterns in familial partial lipodystrophy patients: insights from a population study.
Guidorizzi NR; Valerio CM; Viola LF; Veras VR; Fernandes VO; Lima GEDCP; Flor AC; Araújo JS; Gonçalves Muniz RB; Moreira RO; De Paula FJA; Zajdenverg L; Dantas JR; Godoy-Matos AF; Montenegro Júnior RM; Foss-Freitas MC
Front Endocrinol (Lausanne); 2024; 15():1359211. PubMed ID: 38887266
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.
Ahmad Z; Banerjee P; Hamon S; Chan KC; Bouzelmat A; Sasiela WJ; Pordy R; Mellis S; Dansky H; Gipe DA; Dunbar RL
Circulation; 2019 Aug; 140(6):470-486. PubMed ID: 31242752
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
[TBL] [Abstract][Full Text] [Related]
18. A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adults.
Fukuhara K; Furihata K; Matsuoka N; Itamura R; Ramos V; Hagi T; Kalluru H; Bramson C; Terra SG; Liu J
Clin Transl Sci; 2023 May; 16(5):886-897. PubMed ID: 37002654
[TBL] [Abstract][Full Text] [Related]
19. Familial Partial Lipodystrophy-Literature Review and Report of a Novel Variant in
Rutkowska L; Salachna D; Lewandowski K; Lewiński A; Gach A
Diagnostics (Basel); 2022 Apr; 12(5):. PubMed ID: 35626278
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.
Oral EA; Gorden P; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Brown RJ
Endocrine; 2019 Jun; 64(3):500-511. PubMed ID: 30805888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]